Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. Show more
Location: One World Trade Center, Suite 8500, New York, NY, 10007, United States | Website: https://www.mindmed.co | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.201B
52 Wk Range
$4.70 - $14.43
Previous Close
$12.35
Open
$12.45
Volume
2,320,467
Day Range
$12.43 - $13.45
Enterprise Value
1.048B
Cash
209.1M
Avg Qtr Burn
-28.48M
Insider Ownership
0.61%
Institutional Own.
41.26%
Qtr Updated
09/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
MM120 (lysergide D-tartrate) Details Major depressive disorder | Phase 3 Data readout | |
MM120 (lysergide D-tartrate) Details Anxiety Disorders | Phase 3 Data readout | |
MM402 (R(-)-MDMA) Details Autism spectrum disorders | Phase 2a Initiation |